Gilgamesh Pharmaceuticals Valuation, Funding & Investors
Gilgamesh Pharmaceuticals is valued at $30M as of July 2020.
Last Gilgamesh Pharmaceuticals valuation
$30M
Seed · Jul 2020
Last Gilgamesh Pharmaceuticals funding round
$60M
Series A · Mar 2026
Cumulative funding Gilgamesh Pharmaceuticals raised
$135M
across 6 funding rounds
Key investors in Gilgamesh Pharmaceuticals
Prime Movers Lab
Alumni Ventures
Route 66 Ventures
Satori Capital
Palo Santo Fund
Gron Ventures
About Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a biotechnology company developing small-molecule medicines for mental illness, drawing on medicinal chemistry and the neuroscience of psychedelic compounds. Its proprietary drug discovery platform combines behavioral assessments, electrophysiology, molecular measures of neuroplasticity, and artificial intelligence to design novel drug candidates for conditions such as major depressive disorder, opioid use disorder, and ADHD. Founded in 2019 as a Y Combinator startup and based in New York, its lead candidate, bretisilocin (GM-2505), has entered Phase II trials for moderate to severe major depressive disorder under a collaboration with AbbVie.
Founded
2019
HQ
United StatesWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$30M (Jul 2020)
Sectors
Gilgamesh Pharmaceuticals Valuation
Gilgamesh Pharmaceuticals is currently valued at $30M, based on its seed round in July 2020.
The $2M round included Aera VC, Noveus Capital, Rand Hindi and Pioneer Fund.
Gilgamesh Pharmaceuticals valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jul 2020 | Seed | $30M |
Gilgamesh Pharmaceuticals Funding History
Gilgamesh Pharmaceuticals has raised a total of $135M across 6 funding rounds.
Gilgamesh Pharmaceuticals' first fundraising round was a $2M seed round in July 2020. The most recent completed round was a $60M Series A in March 2026.
Gilgamesh Pharmaceuticals funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2026 | Series A | Satori Capital (lead); Prime Movers Lab | $60M | - | - |
| Feb 2026 | Undisclosed stage | - | $6M | - | Gilgamesh Pharmaceuticals is a discovery and early development biotech company focused on developing small molecules for treating mental illness, leveraging expertise in medicinal chemistry and neuroscience of psychedelic compounds. The company uses a proprietary drug discovery platform that combines behavioral assessments, advanced electrophysiology, molecular measures of neuroplasticity, and artificial intelligence to identify and design novel drugs intended to improve the translation of psychoactive compounds to clinical use. In February 2026, Gilgamesh raised $6.09 million in venture funding. In March 2026, the company entered into a collaboration and option-to-license agreement with AbbVie, a major pharmaceutical company, under which AbbVie made an upfront payment of $65 million with potential option and milestone fees of up to $1.95 billion, positioning Gilgamesh as a key player in the growing industry focus on next-generation psychiatric therapies. |
| Dec 2022 | Series B | Prime Movers Lab (lead); WPSS.bio; Route 66 Ventures; Alumni Ventures; Negev Capital; Satori Capital; Palo Santo Fund; JLS Fund; Gron Ventures | $39M | - | Gilgamesh Pharmaceuticals is a mental health therapeutics company that received backing from Prime Movers Lab and other venture investors. The company raised $39 million in Series B financing led by Prime Movers Lab in 2022, according to Pharmaceutical Business Review, as part of its effort to advance treatments for mental health. Prime Movers Lab has been an investor since the company's Series A round in May 2021 and continued support through the Series B round in May 2022. As of March 2024, Gilgamesh Pharmaceuticals had raised a total of $83.45 million across eight funding rounds, including a $14 million grant from the National Institute on Drug Abuse. The company's investors include Prime Movers Lab, Route 66 Ventures, Palo Santo, and JLS Fund, among others. According to Prime Movers Lab leadership, the firm's technical expertise helped Gilgamesh move into clinical trials faster than expected, demonstrating the operational support provided beyond capital. |
| May 2021 | Series A | Prime Movers Lab (lead); Noetic Fund; Route 66 Ventures; Alumni Ventures; Palo Santo Fund; JLS Fund; Gaingels; Gron Ventures | $27M | - | Gilgamesh Pharmaceuticals is a biotechnology company focused on mental health science, developing psychedelic-related medicines and new chemical entities for treating neuropsychiatric conditions, including non-hallucinogenic psychoplastogens. Founded in 2019 as a Y Combinator startup, it closed a $27 million Series A funding round on May 6, 2021, led by Prime Movers Lab, with participation from Noetic Fund (Noetic Psychedelic Fund LP), Gron Ventures, Route 66 Ventures, JLS Fund, Palo Santo Fund/Investors, and others matching the query investors. The funds were allocated to expand the team with hires like COO and Head of R&D & Chief Business Officer, advance multiple programs toward clinical candidate selection, and broaden its IP portfolio. The company was founded by experienced entrepreneurs, including Dr. Sporn, who previously founded Perception Neuroscience, the first psychedelic space exit to ATAI Life Sciences, and co-founder Andrew Krugel, who later founded Kures. Gilgamesh's pipeline includes lead candidate bretisilocin (GM-2505), a psychedelic compound for moderate to severe major depressive disorder, which entered phase II studies. Post-2021, Gilgamesh raised a $39 million Series B in 2022 with Prime Movers Lab, Alumni Ventures, Gaingels, and others, and received a $14 million grant from the National Institute on Drug Abuse in 2024. In August 2025, it entered a major deal with AbbVie for bretisilocin worth up to $1.2 billion, including upfront and milestone payments. The company operates in the burgeoning psychedelic medicine sector, alongside peers like Delix Therapeutics, Beckley Psytech, and ATAI Life Sciences portfolio firms, amid a 'psychedelic renaissance' highlighted by Prime Movers Lab. |
| Aug 2020 | Seed | Y Combinator (lead); Incisive Ventures; Offline Ventures; What If Ventures; Bossa Invest | $100K | - | - |
| Jul 2020 | Seed | Aera VC; Noveus Capital; Rand Hindi; Pioneer Fund | $2M | $30M | Gilgamesh Pharmaceuticals is a preclinical biotechnology company founded in 2019 and located in New York, NY, developing psychedelics-based treatments for conditions including treatment-resistant depression, opioid use disorder, and ADHD. The company raised a total of $6.95 million across rounds, achieving a post-money valuation of $30 million. Investors in the approximately July 2020 round included Aera VC, Noveus Capital, Pioneer Fund, and Rand Hindi. This funding supported Gilgamesh's pipeline of rapid-acting psychedelic compounds aimed at mental health disorders. |
Who has invested in Gilgamesh Pharmaceuticals?
20 investors have backed Gilgamesh Pharmaceuticals across its funding rounds, including Prime Movers Lab, Alumni Ventures, Route 66 Ventures, Satori Capital, Palo Santo Fund and Gron Ventures.
Lead investors include Satori Capital, Prime Movers Lab and Y Combinator.
Gilgamesh Pharmaceuticals Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Jackson, MS | 3 | Lead | May 2021 | |
| Washington, DC | 2 | Participant | May 2021 | |
| United States | 2 | Participant | May 2021 | |
| Dallas, TX | 2 | Lead | Dec 2022 | |
| Chicago, IL | 2 | Participant | May 2021 | |
| New York City, NY | 2 | Participant | May 2021 | |
| Los Angeles, CA | 2 | Participant | May 2021 | |
 Singapore | 1 | Participant | Jul 2020 | |
 Toronto | 1 | Participant | May 2021 | |
| San Francisco, CA | 1 | Lead | Aug 2020 | |
| Seattle, WA | 1 | Participant | Aug 2020 | |
| San Francisco, CA | 1 | Participant | Jul 2020 | |
| New York City, NY | 1 | Participant | Dec 2022 | |
This data is available for Pro users. Sign up to see all 20 Gilgamesh Pharmaceuticals investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialGilgamesh Pharmaceuticals Competitors
Gilgamesh Pharmaceuticals competitors include listed companies like Gensight Biologics, BeyondSpring, Barinthus Biotherapeutics and Oncocross, and private ones like Aecor Bio and Profluent Bio.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| San Francisco, CA | Private | - | - | $30M | - | |
| San Francisco, CA | Private | - | - | $30M | - | |
 France | Publicly listed | $1K | ($10M) | $30M | 4.5x | |
| United States | Publicly listed | - | ($9M) | $30M | - | |
 United Kingdom | Publicly listed | - | ($63M) | $30M | - | |
 South Korea | Publicly listed | $270K | ($6M) | $29M | - |
Gilgamesh Pharmaceuticals Public Comps
Gilgamesh Pharmaceuticals is still privately-owned, but its public comps include Gensight Biologics, BeyondSpring, Barinthus Biotherapeutics, Oncocross, TAO Synergies, Evaxion, Spirit Scientific Co, Maat Pharma, Sprint Bioscience and Kyntra Bio.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1K | ($10M) | 36474.6x | 4.5x | (4.2x) | - | |||
| - | ($9M) | - | - | (2.7x) | - | |||
| - | ($63M) | - | - | - | - | |||
| $270K | ($6M) | 65.3x | - | (3.0x) | - | |||
| $299K | ($29M) | 109.6x | - | (1.1x) | - | |||
| $8M | ($7M) | 2.9x | 10.3x | (3.0x) | - | |||
| $9M | $2M | 2.9x | - | 14.6x | - | |||
| $5M | ($32M) | 3.9x | 3.4x | (0.6x) | (0.7x) | |||
This data is available for Pro users. Sign up to see all Gilgamesh Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Gilgamesh Pharmaceuticals
| When was Gilgamesh Pharmaceuticals founded? | Gilgamesh Pharmaceuticals was founded in 2019. |
| Where is Gilgamesh Pharmaceuticals headquartered? | Gilgamesh Pharmaceuticals is headquartered in United States. |
| Is Gilgamesh Pharmaceuticals publicly listed? | No, Gilgamesh Pharmaceuticals is a private, VC-backed company. |
| What is Gilgamesh Pharmaceuticals' valuation? | Gilgamesh Pharmaceuticals was last valued at $30M in its seed round in July 2020. |
| How much funding has Gilgamesh Pharmaceuticals raised? | Gilgamesh Pharmaceuticals has raised $135M across 6 funding rounds. |
| What was Gilgamesh Pharmaceuticals' last funding round? | Gilgamesh Pharmaceuticals' last funding round was a $60M Series A in March 2026, led by Satori Capital. |
| Who are Gilgamesh Pharmaceuticals' investors? | Gilgamesh Pharmaceuticals' investors include Prime Movers Lab, Route 66 Ventures, Alumni Ventures, Satori Capital, Palo Santo Fund, JLS Fund, Gron Ventures, Aera VC, Noetic Fund, Y Combinator and 10 others. |
| Which companies are comparable to Gilgamesh Pharmaceuticals? | Companies comparable to Gilgamesh Pharmaceuticals include Aecor Bio, Profluent Bio, Gensight Biologics, BeyondSpring, Barinthus Biotherapeutics and Oncocross. |
See companies similar to Gilgamesh Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.